Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCYC Bicycle Therapeutics	$8.56 +6.5%	$7.96	$6.10 ▼ $28.67	$556.80M	1.41	399,049 shs	501,623 shs
BLUSF BELLUS Health		$9.77	$0.49 ▼ $2.60	$2.35B	1.55	39,610 shs	3.45 million shs
CALT Calliditas Therapeutics AB (publ)	$40.00	$40.00	$15.25 ▼ $43.00	$1.19B	1.77	10,339 shs	N/A
VBIV VBI Vaccines		$0.23	$0.06 ▼ $1.35	$1.87M	2.18	3.66 million shs	29.90 million shs
XENE Xenon Pharmaceuticals	$31.59 -1.7%	$31.57	$26.74 ▼ $46.00	$2.46B	1.1	643,430 shs	1.05 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCYC Bicycle Therapeutics	+3.34%	-0.62%	+5.24%	+8.80%	-65.60%
BLUSF BELLUS Health	0.00%	0.00%	0.00%	0.00%	0.00%
CALT Calliditas Therapeutics AB (publ)	0.00%	0.00%	0.00%	0.00%	+1.83%
VBIV VBI Vaccines	0.00%	0.00%	0.00%	0.00%	-91.05%
XENE Xenon Pharmaceuticals	+1.58%	-2.61%	+1.32%	-8.58%	-23.69%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BCYC Bicycle Therapeutics	3.7244 of 5 stars	4.4	2.0	0.0	0.0	2.4	4.2	0.6
BLUSF BELLUS Health	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CALT Calliditas Therapeutics AB (publ)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VBIV VBI Vaccines	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
XENE Xenon Pharmaceuticals	3.4643 of 5 stars	4.5	4.0	0.0	0.0	1.7	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCYC Bicycle Therapeutics	2.70	Moderate Buy	$24.22	182.97% Upside
BLUSF BELLUS Health	0.00	N/A	N/A	N/A
CALT Calliditas Therapeutics AB (publ)	0.00	N/A	N/A	N/A
VBIV VBI Vaccines	0.00	N/A	N/A	N/A
XENE Xenon Pharmaceuticals	3.00	Buy	$54.82	73.53% Upside

Current Analyst Ratings Breakdown

Latest BCYC, VBIV, BLUSF, XENE, and CALT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/17/2025	BCYC Bicycle Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$32.00 ➝ $25.00
5/14/2025	XENE Xenon Pharmaceuticals	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$55.00
5/13/2025	XENE Xenon Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$50.00 ➝ $47.00
5/13/2025	XENE Xenon Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$58.00 ➝ $55.00
5/13/2025	XENE Xenon Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$53.00 ➝ $53.00
5/13/2025	XENE Xenon Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$55.00 ➝ $55.00
5/13/2025	XENE Xenon Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$60.00 ➝ $55.00
5/7/2025	XENE Xenon Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$55.00
5/5/2025	BCYC Bicycle Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Equal Weight ➝ Equal Weight	$15.00 ➝ $17.00
5/5/2025	XENE Xenon Pharmaceuticals	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
5/2/2025	BCYC Bicycle Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$35.00 ➝ $32.00

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCYC Bicycle Therapeutics	$35.28M	16.80	N/A	N/A	$11.48 per share	0.75
BLUSF BELLUS Health	$30K	0.00	N/A	N/A	$0.25 per share	0.00
CALT Calliditas Therapeutics AB (publ)	$1.60B	0.74	N/A	N/A	$1.06 per share	37.74
VBIV VBI Vaccines	$9.41M	0.00	N/A	N/A	$0.32 per share	0.00
XENE Xenon Pharmaceuticals	$9.43M	257.04	N/A	N/A	$9.90 per share	3.19

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCYC Bicycle Therapeutics	-$169.03M	-$3.14	0.00	N/A	N/A	-790.07%	-25.54%	-21.23%	8/5/2025 (Estimated)
BLUSF BELLUS Health	-$7.01M	-$0.10	N/A	N/A	N/A	-49,910.34%	-48.37%	-45.25%	N/A
CALT Calliditas Therapeutics AB (publ)	-$43.96M	-$1.85	N/A	8.68	N/A	-30.18%	-212.04%	-27.96%	N/A
VBIV VBI Vaccines	-$92.84M	N/A	0.00	N/A	N/A	-881.79%	-525.42%	-45.87%	N/A
XENE Xenon Pharmaceuticals	-$234.33M	-$3.23	0.00	N/A	N/A	N/A	-32.44%	-30.84%	8/14/2025 (Estimated)

Latest BCYC, VBIV, BLUSF, XENE, and CALT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	XENE Xenon Pharmaceuticals	-$1.03	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	BCYC Bicycle Therapeutics	-$0.95	N/A	N/A	N/A	$9.43 million	N/A
5/12/2025	Q1 2025	XENE Xenon Pharmaceuticals	-$0.90	-$0.83	+$0.07	-$0.83	$1.64 million	$7.50 million
5/1/2025	Q1 2025	BCYC Bicycle Therapeutics	-$0.86	-$0.88	-$0.02	-$0.88	$8.67 million	$9.98 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCYC Bicycle Therapeutics	N/A	N/A	N/A	N/A	N/A
BLUSF BELLUS Health	N/A	N/A	N/A	N/A	N/A
CALT Calliditas Therapeutics AB (publ)	N/A	N/A	N/A	N/A	N/A
VBIV VBI Vaccines	N/A	N/A	N/A	N/A	N/A
XENE Xenon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCYC Bicycle Therapeutics	N/A	14.86	14.86
BLUSF BELLUS Health	N/A	13.87	13.87
CALT Calliditas Therapeutics AB (publ)	9.44	2.69	2.59
VBIV VBI Vaccines	N/A	0.34	0.21
XENE Xenon Pharmaceuticals	N/A	17.66	17.66

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCYC Bicycle Therapeutics	86.15%
BLUSF BELLUS Health	N/A
CALT Calliditas Therapeutics AB (publ)	2.83%
VBIV VBI Vaccines	12.26%
XENE Xenon Pharmaceuticals	95.45%

Insider Ownership

Company	Insider Ownership
BCYC Bicycle Therapeutics	22.90%
BLUSF BELLUS Health	24.17%
CALT Calliditas Therapeutics AB (publ)	2.20%
VBIV VBI Vaccines	10.35%
XENE Xenon Pharmaceuticals	5.52%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCYC Bicycle Therapeutics	240	69.25 million	53.40 million	Optionable
BLUSF BELLUS Health	10	159.12 million	N/A	Not Optionable
CALT Calliditas Therapeutics AB (publ)	180	29.79 million	29.14 million	Optionable
VBIV VBI Vaccines	22	28.68 million	25.71 million	Optionable
XENE Xenon Pharmaceuticals	210	76.73 million	72.50 million	Optionable

BCYC, VBIV, BLUSF, XENE, and CALT Headlines

Recent News About These Companies

CenterBook Partners LP Makes New $745,000 Investment in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

July 18 at 11:37 AM | marketbeat.com

TimesSquare Capital Management LLC Has $25.01 Million Stock Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

July 14, 2025 | marketbeat.com

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Average Recommendation of "Buy" from Brokerages

July 10, 2025 | americanbankingnews.com

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Average Recommendation of "Buy" by Brokerages

July 10, 2025 | marketbeat.com

Traders Buy Large Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE)

July 10, 2025 | marketbeat.com

Xenon Pharmaceuticals (NASDAQ:XENE) Shares Cross Below 200 Day Moving Average - Here's Why

July 5, 2025 | marketbeat.com

Xenon Appoints CEO Ian Mortimer as Interim CFO

July 3, 2025 | tipranks.com

Xenon Pharmaceuticals Inc. Added to Russell 3000® and Russell 2000® Indexes in Annual Reconstitution - Nasdaq

June 29, 2025 | nasdaq.com

Xenon Pharmaceuticals Joins Russell 3000® and 2000® Indexes

June 27, 2025 | tipranks.com

Xenon Pharmaceuticals Inc. Added to Russell 3000® and Russell 2000® Indexes in Annual Reconstitution

June 27, 2025 | quiverquant.comQ

Xenon Joins the Russell 3000® and Russell 2000® Indexes

June 27, 2025 | financialpost.comF

Xenon Joins the Russell 3000® and Russell 2000® Indexes

June 27, 2025 | globenewswire.com

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 26, 2025 | financialpost.comF

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 26, 2025 | globenewswire.com

Xenon Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:XENE)

June 26, 2025 | marketbeat.com

Xenon Pharmaceuticals (NASDAQ:XENE) Share Price Passes Below 50 Day Moving Average - What's Next?

June 25, 2025 | marketbeat.com

Xenon Announces Appointment of Darren Cline as Chief Commercial Officer

June 24, 2025 | globenewswire.com

Xenon Pharmaceuticals (XENE) Up 8.7% Since Last Earnings Report: Can It Continue?

June 11, 2025 | zacks.com

Xenon to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

June 3, 2025 | globenewswire.com

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 30, 2025 | globenewswire.com

Fair Value analysis proves accurate as XENE drops 37% from February 2024 peak

May 21, 2025 | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCYC, VBIV, BLUSF, XENE, and CALT Company Descriptions

Bicycle Therapeutics NASDAQ:BCYC

$8.56 +0.52 (+6.47%)

Closing price 04:00 PM Eastern

Extended Trading

$8.31 -0.25 (-2.92%)

As of 07:04 PM Eastern

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

BELLUS Health OTCMKTS:BLUSF

BELLUS Health, Inc. is a biopharmaceutical development company, which engages in the research and development of products that provide health solutions and address critical unmet medical needs. Its products include BLU-5937, KIACTA, AMO-01, and ALZ-801. The company was founded on June 17, 1993 and is headquartered in Laval, Canada.

Calliditas Therapeutics AB (publ) NASDAQ:CALT

$40.00 0.00 (0.00%)

As of 07/17/2025

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.

VBI Vaccines NASDAQ:VBIV

VBI Vaccines Inc., a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus. In addition, it develops coronavirus vaccine candidates that include VBI-2902, VBI-2901, and VBI-2905. The company has collaboration and license agreements with Brii Biosciences Limited; and the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is based in Cambridge, Massachusetts.

Xenon Pharmaceuticals NASDAQ:XENE

$31.59 -0.53 (-1.65%)

Closing price 04:00 PM Eastern

Extended Trading

$31.59 0.00 (0.00%)

As of 04:39 PM Eastern

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time